| Předmět: |
|
| Zdroj: |
Cancer Weekly; 4/11/2024, p1148-1148, 1p |
| Abstrakt: |
A recent study conducted by researchers at the National Cancer Institute (NCI) has shed light on the role of NKX2-1 in the progression of thyroid cancer. The study found that patients with low NKX2-1 mRNA expression had a significantly poorer prognosis compared to those with intermediate and high expression levels. The researchers used a lentivirus-transduced tetracycline-inducible system to overexpress NKX2-1 in advanced thyroid cancer cell lines, which resulted in a significant suppression of cell proliferation and migration. The study suggests that NKX2-1 may act as a tumor suppressor in advanced thyroid cancers by inhibiting cell proliferation and migration through the suppression of epithelial-mesenchymal transition (EMT) transcription factors. Further research is needed to explore the potential of NKX2-1 as a therapeutic target for thyroid cancer. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
